EnteroTrack
Centennial · Founded 2013
About EnteroTrack
EnteroTrack focuses on innovation in gastrointestinal medicine. Its innovative system for diagnosing gastrointestinal inflammation consists of two distinct components which are a collection device and a companion assay. The company's EnteroTracker™ allows simple sampling of esophageal mucosal fluid, which can be then assayed through a commercial, CLIA-approved, laboratory-developed test known as the Esophageal String Test™ (EST). The EST provides a quantitative measure of the likelihood of active disease in a patient, which the clinician uses along with other information to guide therapy, develop food-elimination plans, and in general get a far better understanding of the disease and its inflammatory triggers. Together, this provides a validated, quantitative alternative to endoscopy/biopsy for monitoring EoE patients.
Company Facts
- Founded: 2013
- Legal name: EnteroTrack, LLC
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $250.0K
- Funding stage: Seed
- Last round: Non-Equity Assistance (Feb 2024)
- Website: enterotrack.com
- Phone: [email protected]
Social Profiles
Canonical: https://fsome.com/organization/enterotrack-8429680 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.